Conditions we treat
Our CAR-T therapy programmes target CD19/CD22 dual-target and BCMA — the three targets that cover the disease groups where CAR-T has changed the standard of care.
B-cell lymphoma
B-cell non-Hodgkin lymphomas begin in infection-fighting B lymphocytes. Diffuse large B-cell lymphoma (DLBCL) is the most common type — and the largest group of patients treated with CD19-directed CAR-T therapy worldwide.
Our CD19-directed programme covers relapsed or refractory DLBCL and other B-cell lymphomas after prior lines of therapy.
Learn more about each conditionB-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia is an aggressive cancer of B-lymphocyte precursors in the bone marrow. In patients whose disease has relapsed or resisted treatment, prognosis with conventional options remains poor.
Our dual-target CD19/CD22 programme is designed to reduce antigen escape — the mechanism by which disease evades single-target therapy.
Includes relapsed or refractory disease in adults and children.
Learn more about each conditionMultiple myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow. For patients whose disease has returned after prior lines of therapy, BCMA-directed CAR-T has become an established option.
Our BCMA-directed programme covers relapsed or refractory myeloma after prior treatment lines.
Learn more about each conditionWhether CAR-T is suitable for a specific patient is decided only through the eligibility review. This page is informational and is not medical advice.
The therapy
One construct, two targets.
For B-cell acute lymphoblastic leukemia, our programme uses a dual-target CAR-T: the patient's own T cells, engineered in a single construct to recognise both CD19 and CD22 — two of the most validated targets on B-lineage leukemia cells.
How CAR-T works
T cells are collected from the patient, engineered in the laboratory to carry a chimeric antigen receptor (CAR), multiplied, and returned to the patient in a single infusion — where they seek out and attack leukemia cells.
Why two targets
Leukemia cells can lose the CD19 antigen under treatment pressure — the most common route by which single-target CAR-T fails. Recognising both CD19 and CD22 closes this escape route.
Bicistronic design
Both receptors are carried by one vector and expressed by the same T cell as a single construct — not two separate products mixed at the bedside. Every engineered cell watches both targets.
Validated binding domains
The CD19-binding domain comes from the FMC63 antibody lineage, clinically validated in the world's first approved CAR-T therapies; the CD22-binding domain has demonstrated specific CD22 binding in clinical development.
4-1BB co-stimulation
The co-stimulatory domain 4-1BB supports sustained persistence of the engineered cells and is associated with more gradual expansion — a factor linked to a more manageable side-effect profile.
Your own cells
The product is autologous: made from the patient's own T cells, for that patient only — manufactured in our GMP facility in Ankara and released only after full quality control.
Product details on this page are informational. Full technical documentation, study data and safety profiles are shared with registered physicians through the clinical data package.